IFITm1 Is a Tight Junction Protein That Inhibits Hepatitis C Virus Entry

Abstract

This study defines IFITM1 as an ISG effector with action against HCV entry. Design of therapy regimens to enhance IFITM1 expression should improve the virologic response among HCV patients undergoing treatment with type I IFN.